logo-loader
viewVentriPoint Diagnostics Ltd.

Ventripoint Diagnostics’ VMS+ 3.0 whole heart analysis system cleared by FDA

The cost-effective diagnostic tool for measuring heart function uses 2D ultrasound and is already available in Canada and Europe

VentriPoint Diagnostics Ltd. - Ventripoint Diagnostics’ VMS+ 3.0 whole heart analysis system cleared by the US FDA
The Ventripoint Medical System (VMS) is a device that measures the function of all four chambers of the heart

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCMKTS:VPTDF) announced Thursday that the US Food and Drug Administration has approved the company’s VMS+ 3.0 whole heart analysis system.

The Toronto-based medical device company’s Ventripoint Medical System (VMS) is a device that measures the function of all four chambers of the heart. Approximately 50% of patients with heart failure have dysfunctional right hearts which go undetected and untreated, leading to repeat hospitalizations. The VMS is designed to reduce healthcare costs while improving quality of life in patients with heart disease.

The cost-effective VMS+ 3.0 system diagnostic tool for measuring whole heart function utilizes standard 2D ultrasound. The company said the VMS+ 3.0 system connects to echocardiography machines and uses a proprietary knowledge-based reconstruction technology to create 3D images of the heart and calculates volumes and ejection fractions for all four cardiac chambers with accuracy equivalent to an MRI scan.

READ: Ventripoint Diagnostics has groundbreaking new device to help combat heart disease

In a statement, Ventripoint CEO George Adams said the Candian company was “thrilled” that its innovative heart analysis system can now be used in hospitals across the United States.

“Millions of echocardiograms are performed in the US annually and our goal is to become the premier analysis tool for cardiac imaging in both pediatric and adult hospitals,” said Adams.

Nearly $200 billion is spent every year on battling heart disease in the US. It is one of the leading causes of death for both men and women worldwide, and accurate cardiac measurements are critical for patient care.

The VMS+ 3.0 system is already commercially available in Canada and Europe. In June, the company hit a milestone with the announcement that it had received a license from Health Canada to market the VMS+ 3.0 cardiac system for all patients where the Left Ventricle, Right Ventricle, Left Atrium, and Right Atrium volumes and ejection fractions are warranted or desired. 

Currently there are three children’s hospitals and five cardiac institutions in Canada who have ordered the machine. 

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Quick facts: VentriPoint Diagnostics Ltd.

Price: 0.075 CAD

TSX-V:VPT
Market: TSX-V
Market Cap: $5.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VentriPoint Diagnostics Ltd. named herein, including the promotion by the Company of VentriPoint Diagnostics Ltd. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Ventripoint Diagnostic focussing on sales in 2020 as they...

Ventripoint Diagnostics (CVE:VPT-OTCQB: VPTDF) Executive Chairman and Acting CEO Dr George Adams sat down with Steve Darling from Proactive in Vancouver with news the company has 11 purchase orders in for their echocardiogram system that provides cardiac measurements. Adams telling Proactive...

on 02/20/2020

2 min read